About KEI Europe | Actions | Licensing | Press | Contact

Crown Use Request on T-DM1 in the UK

1 October 2015. KEI Europe, as a member of the Coalition for Affordable T-DM1, submitted a letter to the UK government requesting the government to take several actions to make the breast cancer drug T-DM1 (trastuzumab emtansine) more affordable. The drug made by Roche (trade name Kadcyla) was declared too expensive for the NHS to provide and was only available in England through the Cancer Drug Fund.

Information regarding the problem, the request, and how you can get involved:

An overview of the crisis in access to T-DM1 in the UK:

Members of the Coalition for Affordable T-DM1